New hope is emerging for patients with treatment-resistant metastatic skin cancer. At the European Society of Medical Oncology (Esmo) congress in Paris, the Dutch team generated a lot of interest by presenting their research on cell therapy. This treatment pathway, launched in the 1980s, has been overshadowed by the impressive results of immunotherapy in the 2010s.
But everything comes in time, who knows how to wait. Cell therapy, also called TIL “tumor–infiltratinglymphocytes,” is reunited with light through this work, showing its advantage over ipilimumab (the first immunotherapy allowed on the market in 2011) for some patients in whom first-line treatment does not work. In a randomized phase 3 trial involving 168 patients, 20% of those treated with cell therapy had a complete response after more than three years, compared with 7%…
Source: Le Figaro
